28 results
8-K
EX-99.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
3 Oct 22
Maravai LifeSciences Announces CEO Leadership Transition
4:07pm
, managing complex R&D programs, driving global commercial initiatives, and executing strategic acquisitions. Additionally, he has a stellar reputation
8-K
EX-99.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
28 Jan 22
Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides
8:03am
reputation for quality, their industry leadership and our shared commitment to develop innovative life science tools. We remain committed to our
DRS/A
EX-10.15
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
14 Oct 20
Draft registration statement (amended)
12:00am
on Cygnus’s Products and the goodwill and reputation of Cygnus; (b) avoid deceptive, misleading or unethical practices that are or might be detrimental … into this Agreement is the reputation, business standing, and goodwill already honored and enjoyed by both parties under their present ownership, and accordingly
S-1
EX-10.15
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
29 Oct 20
IPO registration
5:04pm
on Cygnus’s Products and the goodwill and reputation of Cygnus; (b) avoid deceptive, misleading or unethical practices that are or might be detrimental … into this Agreement is the reputation, business standing, and goodwill already honored and enjoyed by both parties under their present ownership, and accordingly
10-K
t26s5mqzb17wk
22 Mar 21
Annual report
4:22pm
424B4
h20gnii0q 1cfmg6ru
23 Nov 20
Prospectus supplement with pricing info
4:36pm
DRS/A
d51ba60b8epx2z hc
23 Oct 20
Draft registration statement (amended)
12:00am
DRS/A
lt30cnb5zo7lle4 700
14 Oct 20
Draft registration statement (amended)
12:00am
DRS
6mx ha6ulr9
8 Sep 20
Draft registration statement
12:00am
S-1
f0iv2gi5zl12trdrb
29 Oct 20
IPO registration
5:04pm
DRSLTR
4icefj6jke849
14 Oct 20
Correspondence regarding draft registration statement
12:00am
8-K
EX-2.1
5qe7g5
10 Aug 21
Maravai Lifesciences Reports Second Quarter Financial Results and Updates 2021 Financial Guidance
4:18pm
424B4
819vch84ij4ob9x pr
13 Sep 21
Prospectus supplement with pricing info
4:16pm